These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16192485)

  • 1. Graft-versus-host disease--from the bench to the bedside?
    Socié G
    N Engl J Med; 2005 Sep; 353(13):1396-7. PubMed ID: 16192485
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective conditioning for acute graft-versus-host disease.
    Lowsky R; Takahashi T; Liu YP; Dejbakhsh-Jones S; Grumet FC; Shizuru JA; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Hoppe RT; Bloch DA; Blume KG; Negrin RS; Strober S
    N Engl J Med; 2005 Sep; 353(13):1321-31. PubMed ID: 16192477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithymocyte globulin in the conditioning regimen: why not?
    Bacigalupo A
    Biol Blood Marrow Transplant; 2014 May; 20(5):597-8. PubMed ID: 24641827
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
    Johansson JE; Brune M; Ekman T
    Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective conditioning for acute graft-versus-host disease.
    Ayala E; Kharfan-Dabaja M
    N Engl J Med; 2005 Dec; 353(25):2718; author reply 2718. PubMed ID: 16371641
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin.
    Yáñez L; Bermúdez A; Insunza A; Romón I; Richard C
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1457-8. PubMed ID: 24972250
    [No Abstract]   [Full Text] [Related]  

  • 16. Company reply to "Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin".
    Janssen S; Blakolmer K
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):575. PubMed ID: 25542157
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
    Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
    N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.